The company’s earnings before interest, tax, depreciation and amortisation slipped to Rs 297.06 crore, down 8%, for the July-September quarter of the current fiscal 2025 as against Rs 324.08 crore for the same quarter in the previous financial year 2024.
Margins narrowed at 21.1% for the three months ended Sept. 30, 2024, as against 23.6% for the same quarter last year.
Shares of Gland Pharma closed 0.20% higher at Rs 1,679.20 apiece on the National Stock Exchange, compared to a 0.47% fall in the benchmark Nifty. The share price has fallen 13.09% in the last 12 months.
Out of 16 analysts tracking the company, eight maintain a ‘buy’ rating on the stock, one recommends ‘hold,’ and seven suggest ‘sell,’ according to Bloomberg data. The average of 12-month analysts’ price targets implies a potential upside of 16.1%.
